Profile picture for user andreich
Andrei Chirileasa
Editor-in-Chief

Andrei studied finance at the Bucharest Academy of Economic Studies and started his journalism career in 2004 with Ziarul Financiar, the leading financial newspaper in Romania, where he worked for ten years, the last six of which as editor of the capital markets section. He joined the Romania-Insider.com team in 2014 as editor and became Editor-in-Chief in 2016. He currently oversees the daily content published on Romania-Insider.com and likes to stay up to date with everything relevant in business, politics, and life in Romania. Andrei lives with his family in the countryside in Northern Romania, where he built their own house. In his free time, he studies horticulture and tends to his family’s garden. He enjoys foraging in the woods and long walks on the hills and valleys around his village. Email him for story ideas and interviews at andrei@romania-insider.com. 

 

The Capital Markets News section is sponsored by the Bucharest Stock Exchange 

BVB
 

Romanian medical services provider MedLife gets EUR 143 mln syndicated loan to continue its expansion

MedLife Medical System (M), the leader of the private medical services market in Romania, has contracted a syndicated loan of approximately EUR 143 million, increasing the existing facilities by EUR 40 million. The group will use the new funds to consolidate its position at the national level and continue its regional expansion.

The syndicate of banks which granted the syndicated loan consists of BCR, as coordinator, mandated lead arranger, documentation agent, facility & security agent and lender, Raiffeisen Bank, BRD Groupe Société Générale and Banca Transilvania, as lead arrangers and lenders.

The new funds will be dedicated to consolidating and expanding the group at the national level through the development of regional hospitals. The expansion of the medical infrastructure and the M&A program are also mong the group's priorities this year. The company will also continue its research efforts, aiming to intensify them through new investments this year.

"We have big plans for the coming period and, even if we are very cautious and connected to the way the health crisis evolves, this does not stop us from daring, innovating, and building new roads where others have never thought to go. We will continue the research initiatives started at the beginning of last year, approaches that not only gave us an important role in society but also positioned us as a regional watchdog in monitoring the pandemic," said Mihai Marcu, President and CEO of MedLife Group.

"As we already announced a month ago, we allocated between EUR 3 and 5 million for the arrangement of a new biosafety III laboratory where we will work for the first time with live viruses, the project being quite advanced. The new laboratory will be inaugurated in Bucharest and will become the most modern research laboratory in genetics, virology, and molecular biology in Romania. At the same time, we maintain as a priority the M&A program but also the consolidation of the medical infrastructure across the country so that the patient can have swift access to medical services everywhere," he added.

MedLife says it has 3-4 advanced discussions for potential takeovers at the national level and 1-2 at the regional level.

MedLife Group ended 2020 with pro-forma consolidated sales of EUR 251 million, up by 25.5% compared to the same period last year, being one of the largest players in the region. According to the company's representatives, the figures budgeted for 2021 at consolidated level show a 15% increase in sales and stable profitability (EBITDA margin). The budgeted figures do not include the acquisitions announced at the end of 2020, which will be added as the completion procedures are finalized.

MedLife's shares, which are trading on the Bucharest Stock Exchange, are up 5.8% since the beginning of this year, after doubling their price in 2020. The company currently has a market capitalization of RON 1.58 bln (EUR 320 mln).

editor@romania-insider.com

(Photo source: the company)

Normal
Profile picture for user andreich
Andrei Chirileasa
Editor-in-Chief

Andrei studied finance at the Bucharest Academy of Economic Studies and started his journalism career in 2004 with Ziarul Financiar, the leading financial newspaper in Romania, where he worked for ten years, the last six of which as editor of the capital markets section. He joined the Romania-Insider.com team in 2014 as editor and became Editor-in-Chief in 2016. He currently oversees the daily content published on Romania-Insider.com and likes to stay up to date with everything relevant in business, politics, and life in Romania. Andrei lives with his family in the countryside in Northern Romania, where he built their own house. In his free time, he studies horticulture and tends to his family’s garden. He enjoys foraging in the woods and long walks on the hills and valleys around his village. Email him for story ideas and interviews at andrei@romania-insider.com. 

 

The Capital Markets News section is sponsored by the Bucharest Stock Exchange 

BVB
 

Romanian medical services provider MedLife gets EUR 143 mln syndicated loan to continue its expansion

MedLife Medical System (M), the leader of the private medical services market in Romania, has contracted a syndicated loan of approximately EUR 143 million, increasing the existing facilities by EUR 40 million. The group will use the new funds to consolidate its position at the national level and continue its regional expansion.

The syndicate of banks which granted the syndicated loan consists of BCR, as coordinator, mandated lead arranger, documentation agent, facility & security agent and lender, Raiffeisen Bank, BRD Groupe Société Générale and Banca Transilvania, as lead arrangers and lenders.

The new funds will be dedicated to consolidating and expanding the group at the national level through the development of regional hospitals. The expansion of the medical infrastructure and the M&A program are also mong the group's priorities this year. The company will also continue its research efforts, aiming to intensify them through new investments this year.

"We have big plans for the coming period and, even if we are very cautious and connected to the way the health crisis evolves, this does not stop us from daring, innovating, and building new roads where others have never thought to go. We will continue the research initiatives started at the beginning of last year, approaches that not only gave us an important role in society but also positioned us as a regional watchdog in monitoring the pandemic," said Mihai Marcu, President and CEO of MedLife Group.

"As we already announced a month ago, we allocated between EUR 3 and 5 million for the arrangement of a new biosafety III laboratory where we will work for the first time with live viruses, the project being quite advanced. The new laboratory will be inaugurated in Bucharest and will become the most modern research laboratory in genetics, virology, and molecular biology in Romania. At the same time, we maintain as a priority the M&A program but also the consolidation of the medical infrastructure across the country so that the patient can have swift access to medical services everywhere," he added.

MedLife says it has 3-4 advanced discussions for potential takeovers at the national level and 1-2 at the regional level.

MedLife Group ended 2020 with pro-forma consolidated sales of EUR 251 million, up by 25.5% compared to the same period last year, being one of the largest players in the region. According to the company's representatives, the figures budgeted for 2021 at consolidated level show a 15% increase in sales and stable profitability (EBITDA margin). The budgeted figures do not include the acquisitions announced at the end of 2020, which will be added as the completion procedures are finalized.

MedLife's shares, which are trading on the Bucharest Stock Exchange, are up 5.8% since the beginning of this year, after doubling their price in 2020. The company currently has a market capitalization of RON 1.58 bln (EUR 320 mln).

editor@romania-insider.com

(Photo source: the company)

Normal
 

Romania Insider Free Newsletters